Now that horse is out of the barn... a few important points about KARMMA-3 #mmsm @paurotero @NBahlis @MyelomaTeacher #myeloma

1/X - First randomized phase 3 trial to show clinical benefit for Car-T cell therapy in MM. That is HUGE.

2/x Population is much more similar to KarMMa1 than population of prior trials with "2-4 LOT". Eligibility required CD38 exposure. One more indication that refractoriness, not LOT matters.

3/x - We can criticize control arm all we want but there is NO REGIMEN validated by a randomized trial with clinical benefit in CD38-exposed 2-4 LOT.

4/x- We will hear "but XYZ has a mPFS of 27 months..." Performance of a regimen depends far more on the disease/population than on regimen itself. We can't in good faith quote those numbers.

5/5 Performance of control arm does not surprise me. It replicates what was seen in MAMMOTH and LOCOMMOTION. Again, Refractoriness>>>>LOT.
www.nature.com/articles/s41375-022-01531-2

pubmed.ncbi.nlm.nih.gov/34802043/

Like in a bad informercial.... there is one more thing! Both arms are analyzed from randomization. Patients who collect but are not infuse are COUNTED in ORR and PFS (Unlike KARMMA and CARTITUDE-1). let's not compare. @VincentRK @Mohty_EBMT @AjayNookaMD @nsc_natalie